Maze Therapeutics (MAZE) Other Non-Current Liabilities (2024 - 2026)

Maze Therapeutics has disclosed Other Non-Current Liabilities across 3 years of filings, most recently posting $388000.0 for Q1 2026.

• Other Non-Current Liabilities for Q1 2026 came in at $388000.0, down 61.43% year-over-year; the trailing twelve-month figure through Mar 2026 was $388000.0 (down 61.43% YoY), and the FY2025 annual result was $1.1 million, up 12.9% from the prior year.
• Other Non-Current Liabilities came in at $388000.0 for Q1 2026 at Maze Therapeutics, down from $1.1 million in the prior quarter.
• In the past five years, Other Non-Current Liabilities ranged from a high of $1.1 million in Q4 2025 to a low of $388000.0 in Q1 2026.
• The 3-year median for Other Non-Current Liabilities is $1.0 million (2025), against an average of $939666.7.
• Across the five-year window, Other Non-Current Liabilities gained 12.9% in 2025 and sank 61.43% in 2026, its largest moves.
• Maze Therapeutics' Other Non-Current Liabilities stood at $969000.0 in 2024, then increased by 12.9% to $1.1 million in 2025, then plunged by 64.53% to $388000.0 in 2026.
• The last three Other Non-Current Liabilities figures came in at $388000.0 (Q1 2026), $1.1 million (Q4 2025), and $1.1 million (Q3 2025), per Business Quant data.